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ABSTRACT
Flavones are polyphenol natural products that are known to have neuroprotective effects
against many diseases caused by the formation of reactive species. Flavonoids are subgroup of
flavones and they are believed to function as antioxidants. Specifically, they target free radicals
and eliminate its harmful effect on the cell.
Fluoroflavones were designed to improve the potency of the antioxidant activity and
potentially be used as neuroprotective agents. A monofluorinated and trifluoromethylated flavone
were

synthesized

by

using

commercially

available

fluorination

reagents,

N-

fluorobenzenesulfonimide; and Togni’s or Umemoto's respectively. After the synthesis of the
desired flavones and their monofluorinated and trifluoromethylated derivatives, biological testing
was conducted. First, antioxidant activity was evaluated by using DPPH antioxidant assay and
displayed that the fluorinated flavones are more potent compared to their non-fluorinated
derivatives. Second, 19F NMR experiments were conducted to investigate the effect of fluorination
on the antioxidant activity of flavones
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LIST OF ABBREVIATIONS OR SYMBOLS
°C

Celcius

CoQ10

Coenzyme Q10

DPPH

2,2-diphenyl-1-picrylhydrazyl

EC50

Half maximal effective concentration

FDA

Food and drug administration

GSH

Glutathione

Hex

Hexanes

h

Hour

IC50

Half maximal inhibitory concentration

LPH

Lactase- phlorizin hydrolase

MBP

Metal-binding proteins

MEL

Melatonin

NFSI

N-fluorobenzenesulfonimide

NMR

Nuclear magnetic resonance

RNS

Reactive nitrogen species

ROS

Reactive oxygen species

rt

Room temperature

SAR

Structure–activity relationship

THF

Tetrahydrofuran

TLC

Thin layer chromatography

UA

Uric acid

UGT

UDP-glucuronosyltransferase

UV

Ultraviolet

iv

ACKNOWLEDGMENTS
First, I would like to express my sincere gratitude to my advisor Prof. David A. Colby for
his continuous support, motivation, immense knowledge and most importantly his patience in my
ongoing learning journey. Dr. Colby is the ultimate mentor that I needed to improve my research
skills and I’m grateful to have this opportunity. I would like to acknowledge University of Hail
and the the Saudi Arabian Cultural Mission (SACM) for the financial support. Besides my
advisor, I would like to thank the rest of my thesis committee: Dr. Sudeshna Roy, and Dr. Nicole
Ashpole, for their insightful comments and encouragement.

My sincere thanks also go to my current lab mates, Reem and Amna, in which we share
great laughs and a lot of NMR time, and to the previses ones, Munia and Hari who both taught
me so many techniques in which I will be always grateful. I would like to extend my
appreciation to the BMS department and to everyone who gave me access to their laboratory and
research facilities, especially our MedChem neighbors, the Roy lab which includes; Sweta,
Shamba, Sampad and Tomayo, and also the Le lab which includes; Nicholas, Imran and
Imdadul. I also want to thank my friends in the department; Hayley, Alaa, Abidah, Omer,
William, Alysia, Shukria, Hanan and Barbara, and most importantly a special thanks for my
sister Alia, I’m blessed to have a sister like you in my life.

v

TABLE OF CONTENTS
Abstract ………………………………………………………………………….…….........…….ii
Dedication…………………………………………………………………………….................. iii
List of Abbreviations and Symbols……………………………………….…………..………….iv
Acknowledgments…………………………………………………………………...………....… v
List of Tables………………………………………………………………....……………..…... xi
List of Figures………………………………………………………..…………………….….…. x
List of Schemes……………………………………………………………...…..………………..xi
1. Introduction……………..……………………………………………….……..……………... 1
1.1 Flavonoid: …………….………...…………..…………….….....……………………. 1
1.1.1 Flavones: A Polyphenol Natural Product …………....………...…...…….. 1
1.1.2 Metabolism of Flavones: ………………………………………..…...…….3
1.1.3 Flavones as Antioxidants: ………………………………….......…...……. 5
1.2 Oxidation: ………………….…………..…...…..……………….…….......…...…….. 6
1.2.1 Oxidants………………………….…………..…...…..………...……...….. 6
1.2.2 Antioxidant ……………………………………………………..……….... 6
1.3 Fluorine in Medicinal Chemistry ………....…………...……..…..…..…………..…... 9
vi

1.4 Fluorinated Flavonoids ………...………...………….……..…...…..………………. 10
1.4.1 Monofluorinated Flavone……………………….……….…….....…......... 11
1.4.2 Trifluoromethylated Flavone……….…………………….…….....….….. 13
2. Synthesis of Flavonoids and Fluorinated Flavonoids …....…………………….…........……..14
2.1 Design strategy…………………….………………………..………...…...………..14
2.2 Flavonoid synthesis…………………….…………………………….…..……..…..15
2.3. Monofluorination: …………..………………..………………………..…..….…..17
2.4. Trifluoromethylation…………..………………..………..…………..………...…..19
3. Biological Evolution of The Fluorinated Flavonoids …………………………………...……23
3.1 DPPH antioxidant assay……………………………..……………..…..….…..……23
3.1.1 Results………………….……………………….…..…..………..……...…25
3.2 Neuroprotective assay …………...……………………..………….….……………28
3.2.1 Results………………….……………………….…..…..………..……...…28
4. Conclusion …………………….………..…………………..…..…..……………………...…30
5. Experimental Details………………………………………………………..…….………...…31
5.1 Synthesis of Flavonoids…………..………………………………...…..………...…31

vii

5.2 Synthesis of Monofluorinated Flavonoids ……………………………...…….....…34
5.3 Synthesis of Trifluoromethylated Flavonoids………………….………..….………37
5.4 The DPPH antioxidant assay ……………………….…………………….….…..…38
5.4.1 Preparation………………………..…………………..…..…….…..……38
5.4.2 Calculation………………………..…………………..…..…….…..……38
5.5 Neuroprotective assay ……………………….………………...………….…..……40
References…………………………………………………………………………...…….…......41
Appendix………………………………………………………………………...……..……..… 44
Vita……………………………………………………...……………………...……….…..……56

viii

LSIT OF TABLES
1.1 Main endogenous antioxidant……………………………………………………..…….… 8
2.1 Fluorination of β-diketone intermediate with NFSI………………..…………….......…… 17
2.2 Synthesis of fluorinated β-diketone intermediate ……………………….……..….....…… 20
3.1 DPPH scavenging activity of hydroxy-flavones……………………………..……....….… 24
3.2 Flavones used in DPPH assay and their EC50 values……………………...……......…...… 26
5.1 96-well plate arrangement……………………………………………….…….……….…. 39

ix

LSIT OF FIGURES
1.1 Basic structure of flavonoids.………………………....…..…………………………………. 1
1.2 Classes of flavonoids.………………………...………………………….……………………2
1.3 Metabolism of flavones.………………………......…..…………………….………………... 4
1.4 Structure of flavone…………………………...…..…...……………...…….…….…………...5
1.5 Structure of 5-fluorouracil ………….…………...…..…...….…………….………….…..…..9
1.6 Structure of fluoxetine………………...…..…...…………………….……...….........……..…9
1.7 Structure of 3',4',7,8-tetrahydroxyflavone and 3',4',7,8-tetrahydroxyfluoroflavone...….……11
2.1: Structures of Togni’s reagents……..….…….……………....………………………....……19
3.1 DPPH assay results……...…………..……….……………....………………………....……27
3.2 Structures of MTS …...…………..……….……………....……………………….........……28
3.3 Neuroprotective assay results …...………….………………………...………............……29
5.1 Procedure for DPPH assay….....………….………………………….....………............……39
5.2 Procedure for neuroprotective assay…...………….….………………...………............……40

x

LIST OF SCHEMES
1.1 Fluorination of flavone by using fluorinating reagents ……………...……………….…… 10
1.2 Fluorination of flavone by using elemental fluorine …………....…...……..……….….… 10
1.3 Synthesis of monofluorinated flavone…………....…...……..……………………....….… 12
1.4 Synthesis of trifluoromethylated flavone…………....…...…………………….…….….… 13
1.5 Trifluoromethylation the flavone…………....…...……..…….………………………....… 13
2.1 The retrosynthesis of flavone....…...……..…….………………………………...……....… 14
2.2 Route toward the desired flavone 6….…………..……………………………….....…….... 15
2.3 Fluorination and trifluoromethylation approaches ……………………..……….....…….... 16
2.4 Route toward the desired monofluorinated flavone………..…….…….....…………..….... 18
2.5 Fluorination of β-diketone intermediate with Togni’s reagent……..……………….…...... 19
2.6 Synthesis of fluorinated β-diketone intermediate with Togni’s reagent…..……………..... 20
2.7 Radical trifluoromethylation by using trifluoroiodomethane gas…..…………………....... 21
2.8 Trifluoromethylation of flavone by using Umemoto′s and Togni′s reagent………..…….... 22
2.9: Trifluoromethylation of flavone by using Umemoto′s and Togni′s reagent then
demethylation with hydrobromic acid…..…………………………………………………….... 22

xi

CHAPTER 1
INTRODUCTION
1.1 Flavonoid:
Polyphenols are secondary metabolites found in many plants. All characterized by the
presence of phenol rings, and they can be subdivided to two main classes depending on their
structure; flavonoid and non-flavonoid. The non-flavonoid includes: stilbenes, lignans and
phenolic acids, which can be further divided into two main types, benzoic acid and cinnamic acid,
while flavonoids are subdivided into six main types which will be discussed later. [1]

Figure 1.1: Basic structure of flavonoids.
1.1.1 Flavones: A Polyphenol Natural Product:
Flavones are a subgroup of flavonoids, which are synthesized in plants from three building
blocks phenylalanine, tyrosine, and malonate [2]. The general structure of flavonoids consists of
three six-membered rings, two aromatic carbon rings, benzopyran (A and C rings) and benzene (B
ring), that vary in the degree of oxidation and substitutions (Figure 1). Flavonoids can be divided
into six subgroups based on the degree of the oxidation of ring C. The main subgroups are (1)
flavonols, (2) flavones, (3) isoflavones, (4) flavanones, (5) flavanols, and (6) anthocyanidins as
shown in (Figure 2). [3]
1

Figure 1.2: Classes of flavonoids.

Flavonoids are generally found in vegetables and fruits like apples, cauliflower, and
carrots, and also in beverages like tea, coffee and red wine. Flavonoids give fruits, flowers and
even the leaves different shades of color which will help the plant to attract pollinating insects,
and in contrast, flavonoids can have a protective response to harmful insects. Because of their
ability to absorb UV radiation, flavonoids can absorb the harmful sun radiation and function as
catalysts in many photosynthesis processes. [4]
The total dietary intake of flavonoids as antioxidants range between 50 and 1000 mg/day,
which is very high when compared to other natural antioxidants like vitamin C and vitamin E, that
are around 10 and 100 higher than flavonoids daily dose, respectively.

[5]

Flavonoids can be

absorbed in many forms, either with the glycosides or without it, or even as phenolic acids. All of
the three forms have antioxidant activity in different degrees.

2

1.1.2 Metabolism of Flavones
In general, flavonoids undergo extensive metabolism by methylation, glucuronidation or
sulfation; due to the several hydroxyl groups found in their structures. This rapid metabolism
affects its absorption after oral administration. Fortunately, one of these enzymatic pathways ( Omethylation ) will increase the stability and distribution of flavonoids and hence increase their
bioavailability [5]. The majority of flavones in plants are found conjugated as 7-O-glycosides, and
the metabolic transformations will effect both the glycone moiety and the aglycone flavone. The
major metabolic conversions are: 1) conversion of flavone 7-O-glucoside to flavone aglycone by
lactase-phlorizin hydrolase (LPH) in small intestine, 2) conversion of flavone aglycone to flavone
glucuronide by UDP-glucuronosyltransferase (UGT) in both liver and small intestine, 3)
conversion of aglycone flavone to the flavone sulfate by sulfotransferase in the liver, and 4)
conversion of flavone 7-O-glucoside to flavone aglycone and 3-(4-hydroxyphenyl) propionic acid
by normal flora of large intestine (Figure 3). [6]

3

Figure 1.3: Metabolism of flavones
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1.1.3 Flavones as antioxidants:
Flavonoids display three key structural features in order to function as radical scavenger;
ring B must have a catechol group, ring C must have a 2,3-double bond in conjugation with a 4oxo group, ring A must have two hydroxy groups at 3- and 5. All the previous points are
responsible for electron delocalization that is necessary to stabilize the free radicals [7] (Figure 1.4).
It was reported that flavonoids function as antioxidants by a radical scavenging mechanism.
Although this is true in vitro, a different mechanism is has been proposed in vivo. Ursini suggested
that flavonoids induce endogenous antioxidant activity by a signaling pathway rather that radical
scavenging. [8] This pathway involves oxidative activation of the NF-E2-related factor. It has been
reported that radical scavenging is not as effective in vivo when it’s compared with other stronger
endogenous antioxidants. [8]

Figure 1.4: Structure of flavone.
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1.2 Oxidation:
In chemistry, oxidation is defined as the removal of electrons from one reactant to another.
Oxidation is always linked with reduction reactions and are usually referred as redox reactions. In
biology, the same concept is applied. [9]
1.2.1 Oxidants:
Reactive species belong to two types of reactive molecules: reactive oxygen species (ROS)
and reactive nitrogen species (RNS). The term ROS include both free radical and non-free radical
species like hydrogen peroxide, molecular oxygen, and ozone. [10] ROS is a normal byproduct in
many aerobic metabolisms and is regulated by NADPH. [11] It has an essential function in cellular
signaling and communications. Damage to cellular tissue may occur when the intracellular level
of ROS is elevated, which is known by oxidative stress.

1.2.2 Antioxidants:
An antioxidant is a nucleophilic reductant that prevents oxidation of an another molecule,
either by reducing the free radicals or preventing their formation.

[9]

It can be endogenous and

exogenous. The endogenous include two main categories which are both complementary to
enzymatic and non-enzymatic defenses. The enzymatic defenses are enzymes that prevent the
formation of free radicals by metabolizing reactive oxygen species like hydrogen peroxide,
superoxide, oxygen singlet, and lipid peroxides. Examples of antioxidant enzymes include Cu/Znsuperoxide dismutase, catalase, Se-glutathione peroxidase and glutathione reductase. [2] The nonenzymatic defenses can inactivate free radicals immediately, and they are further subdivided into
intracellular and extracellular processes. The most common ones are the metal-binding proteins
(MBPs), coenzyme Q10 (CoQ10), glutathione (GSH), uric acid (UA) and melatonin (MEL).

6

The question is, how these different types of antioxidant complement each other? The
answer is summarized in the first, second, and third line of defenses against ROS. [12] The first line
is the most powerful one and it includes both enzymatic and non-enzymatic defenses. Each one of
these antioxidant functions in a distinctive manner. The Cu/Zn-superoxide dismutase is a
metalloenzyme that catalyzes the disproportionation (simultaneously oxidization and reduction)
of superoxide free radical (O2•–) to form hydrogen peroxide and molecular oxygen (Table 1.1).
Another enzymatic defense is catalase (CAT) which is a heme-containing enzyme that can
covert hydrogen peroxide to molecular oxygen and water in a two-step reaction, a reduction and
oxidation.[13] Furthermore, Se-glutathione peroxidase is a selenoenzyme in which hydrogen
peroxide is reduced to water and glutathione (GSH) is oxidized to the glutathione disulfide
(GSSG). [14]
The other part of the first line defenses is the non-enzymatic substances which are proteins
that inhibit the formation of free radicals by transition metal ion binding mechanism, examples
include, albumin ceruloplasmin and ferritin. Those non-enzymatic substances that have the ability
to rapidly inactivate free radicals, like coenzyme Q10 (CoQ10), glutathione (GSH), uric acid (UA)
and melatonin (MEL). The third line of defense is the repairing step which involve enzymatic
antioxidants that will repair the damage generated by free radicals in DNAs, proteins, cell
membrane and other cell organelles. [9]

7

Table 1.1: Main endogenous antioxidant.
Name of the enzyme

Main target

The resulted reaction

Cu/Zn-superoxide dismutase

superoxide free radical

2 HO2 → O2 + H2O2

Catalase

hydrogen peroxide

2 H2O2 → 2 H2O + O2

Se-glutathione peroxidase

hydrogen peroxide

2GSH + H2O2 → GS–SG + 2H2O

Endogenous antioxidants are known to be stronger than exogenous ones, but the balance
between ROS and antioxidants is always changing. In other words, oxidative stress is happening,
whether the cause was from internal factors like inflammation or cancer or external factors like
environmental pollutants such as smoking, radiations or even metals. Also, normal factors like
aging can affect oxidation state. The need for exogenous antioxidants is to support the endogenous
antioxidants and prevent any possible damage generated by the free radicals is clear. Exogenous
antioxidants are substances that can be found in diet or from certain supplements. The most
common exogenous antioxidant are vitamins like vitamin E and vitamin C, and polyphenols, like
flavonols, flavones, and anthocyanidins. Most the dietary antioxidant can be found in fruits,
vegetables and fruit-based beverages line wine and tea.

8

1.3. Fluorine in Medicinal Chemistry
Introducing a fluorine atom into a biologically active molecule is known to produce a
significant impact. It is believed that 25% of drugs in the pharmaceutical market contain at least
one fluorine atom.

[15]

Having high electronegativity and a small molecular size makes fluorine

atom valuable in drug design. [16] Hydrogen and fluorine have similar molecular size, which makes
fluorine a good alternative for the strict requirements at enzyme receptor sites,

[17]

even though

their Van Der Waals radii are not similar (F = 1.47 Å, H = 1.20 Å). [18] In addition, fluorine often
increases lipophilicity and therefore improves the pharmacokinetics properties like absorption and
distribution

[17]

and enhances binding affinity.

[16]

5-Fluorouracil (Efudex®) is one of the oldest

fluorinated drugs (Figure 1.5). This antineoplastic agent was synthesized by Heidelberger in 1957
and function by interfering with the synthesis of thymidylate.

[15]

Another well-known example of fluorine containing drugs is the antidepressant fluoxetine
which was approved by the Food and Drug Administration (FDA) in 1987. Fluoxetine (Prozac®)
contains a trifluoromethyl group in the para-position of the phenol ring. The structure–activity
relationship indicates that the addition of trifluoromethyl increases the selectivity for the serotonin
receptor by 6-fold when compared to the non-fluorinated parent compound. [15]

Figure 1.6: Structure of fluoxetine

Figure 1.5: Structure of 5-fluorouracil

9

1.4. Fluorinated Flavonoids
Flavones are fluorinated to increase their potency by preventing the extensive
metabolism, like methylation, glucuronidation or sulfation. Many fluorinated flavonoids have
been the synthesized by using a variety of methods. A fluoroflavone can be accessed by using
acetophenone derivatives as starting materials followed by electrophilic or radical fluorination.
[16]

The other method involves the use of elemental fluorine on a flavone followed by

dehydrofluorinaion to the monofluoroflavone by adsorbing the intermediate on a silica gel
(scheme 1.2).

Scheme 1.1: Fluorination of flavone by using fluorinating reagents.

Scheme 1.2: Fluorination of flavone by using elemental fluorine. [15]
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1.4.1 Monofluorinated Flavone
Many fluorinated flavones has been synthesized and tested in the literature. One example
is the work of Vanotti in which the 3-fluorotetrahydroxy flavone was synthesized and tested
against cancer as telomerase inhibitors. The fluorinated flavone displayed a 13-fold reduction in
IC50 for inhibition of telomerase activity compared to the non-fluorinated molecule. The IC50 of 3fluorotetrahydroxy flavone was 0.6 μM while for 3',4',7,8-tetrahydroxyflavone it 7.8 μM. [20]

Figure 1.7: Structure of 3',4',7,8-tetrahydroxyflavone and 3',4',7,8-tetrahydroxyfluoroflavone

The

3-fluorotetrahydroxy

flavone

was

synthesized

by

reacting

N-

fluorobenzenesulfonimide with the diketone intermediate in anhydrous dichloromethane for seven
days to afford the product in 28% yield. The mono-fluorinated intermediate was then cyclized by
refluxing in acidic conditions to give the product in 82% yield. Compound 4 was demethylated by
using boron tribromide in dichloromethane in 71% yield. (scheme 1.3)

11

Scheme 1.3: Synthesis of monofluorinated flavone
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1.4.2 Trifluoromethylated Flavone
There is only one reported trifluoromethylated flavone derivative in the literature by Qing
and co-workers in 2005, in which they synthesized the trifluoromethylated flavone by
trifluoromethylation of 3-iodoflavonoid derivatives with methyl 2,2-difluoro-2-(fluorosulfonyl)
acetate and copper iodide as catalyst (Scheme 1.4).

[21]

Qing and co-workers also

trifluoromethylate the flavone using trimethyl (trifluoromethyl) silane, also known as Ruppert's
reagent tetramethylammonium fluoride as catalyst. The intermediate was then treated with
hydrochloric acid (Scheme 1.5). [21]

Scheme 1.4: Synthesis of trifluoromethylated flavone

Scheme 1.5: trifluoromethylation the flavone
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CHAPTER 2
SYNTHESIS OF FLAVONOIDS AND FLUORINATED FLAVONOIDS
2.1 Design strategy:
The retrosynthesis of flavone is carried out by an intermolecular cyclization of compound
4, followed by intermolecular rearrangement of compound 3. This arrangement is known as BakerVenkataraman reaction which involves a reaction of compound 3 with base to form a 1,3-diketone.
The last step is a simple coupling of compound 1 with 2 under basic conditions (Scheme 2.1).

+

Scheme 2.1: The retrosynthesis of flavone
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2.2 Flavonoid synthesis:
The synthesis of the desired flavone compound 4 starts with two commercially available
staring

materials,

compound

1

(2'-hydroxyacetophenone)

and

compound

2

(3,4,5-

trimethoxybenzoyl chloride) according to Vanotti )Scheme 2.2). [20] Coupling compound 1 with
compound 2 in pyridine results in forming the ester 3 in 40% yield. Then, treating the ester 3 with
potassium hydroxide forms the di-ketone 4, by a Baker-Venkataraman rearrangement.

[16]

Cyclization of compound 4 by refluxing with acetic acid and hydrochloric acid and demethylation
by using boron tribromide provides the target flavone 6 (Scheme 2.2).

+

Schemes 2.2: Route toward the desired flavone 6
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There are limited number of methods that are available for selective carbon-fluorine bond
formation when compared to other carbon-halogen bond forming reactions.

[18]

We have two

targets, which are the monofluorination and trifluoromethylation products. Both require
electrophilic fluorinating reagents, and then cyclization to the targeted flavone (Scheme 2.3).

Scheme 2.3: Fluorination and trifluoromethylation approaches
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2.3.Monofluorination:
N-Fluorobenzenesulfonimide (NFSI) was reported by Barnette in

1984.

[18]

This

electrophilic fluorinating reagent is stable, easily prepared and purified. [24] The monofluorinated
flavone 10 was synthesized by reacting compound 4 with NFSI for a week in dichloromethane or
in a mixture of dichloromethane and acetonitrile with a yield of 28% and 37% respectively. This
method uses pyridine as a solvent. We screened different temperatures to observe the selectivity
and reactivity of NFSI with the diketone 4. As the temperature increased from 0 °C to 50 °C more
of the mono-fluorinated diketone 10 is observed compared to di-fluorinated diketone 11. At
100 °C, only the cyclized fluorinated form 12 is observed which give us a more efficient and direct
method to access the final product. The yield increased from 32% to 72% and the reaction time
decreased from 7 days to 12 h (Scheme 2.4 and Table 2.4).

Table 2.1: Fluorination of diketone intermediate with NFSI

Entry

19

Temperature

F NMR ratio

10

11

12

1

0 °C

1

2.4

-

2

24 °C

1

2.2

-

3

50 °C

1

-

0.1

4

100 °C

-

-

1

17

Scheme 2.4: Route toward the desired monofluorinated flavone
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2.4. Trifluoromethylation
Togni I, 1-(trifluoromethyl)-1,2- benziodoxol-3(1H)-one, and Togni II, trifluoromethyl1,3-dihydro- 3,3-dimethyl-1,2-benziodoxole, are two hypervalent iodine species that function as a
source of an electrophilic trifluoromethyl group (Figure 2.1). Togni’s reagent needs to be activated
first by Lewis acids, Brønsted acids or even metals. Copper iodide was selected because it is one
of the most widely used catalysts for activating of Togni’s reagents. [25]

Figure 2.1: Structures of Togni’s reagents

First, we tried to trifluoromethylate the protected β-diketone 7 with Togni I and copper
iodide in THF or pyridine, with bases like LDA or BDU, or without any base. None of the reactions
produced the target 9. So we repeated the same process with the unprotected β-diketone 4, which
also did not work. Umemoto’s reagent also failed to yield the desired product 9 or 14.

Scheme 2.5: Fluorination of the protected β-diketone intermediate with Togni’s reagent
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Scheme 2.6 Synthesis of fluorinated β-diketone intermediate with Togni’s reagent

Table 2.2: Synthesis of fluorinated β-diketone intermediate
Entry
1
2

Solvent
(1 mL)
pyridine
pyridine

Reagent
[1.2]
Togni’s I
Togni’s I

Activating
Agent
Cul [0.2]
Cul [0.2]

3
4
5
1

CH3CN
CH3CN
EtOAc
CH2Cl2

Togni’s II
Togni’s II
Togni’s II
Umemoto's

2

CH2Cl2

3

DBU
ــــــ

Temperatur
e (°C)
rt
rt

Time
(h)
24
24

Cul [0.2]
Cul [0.2]
TBAI [0.1]
Cul [0.2]

ــــــ
ــــــ
ــــــ
DBU

40
rt
80
rt

12
24
24
24

Umemoto's

Cul [0.2]

ــــــ

rt

24

pyridine

Umemoto's

Cul [0.2]

ــــــ

40

12

4

DMF

Umemoto's

K2CO3 [3]

rt

24

5

DMF

Umemoto's

TBAI
[0.05]
TBAI
[0.05]

K2CO3 [3]

40

24

20

Base

None of the previous experiment listed in (Table 2.2) led to the formation of the
trifluorinated products. Another approach was taken using trifluoroiodomethane gas in a radical
trifluoromethylation mechanism reagent, but again the reaction was not successful due to nonselective fluorination (Scheme 2.7). The last approach was to trifluoromethylate a flavone by using
Umemoto′s reagent or Togni I and copper iodide in dimethylformamide as seen in Scheme 2.8. [26]
This method resulted in the trifluoromethylation of the flavone in 20% 19F NMR yield. Based on
this finding, the desired methoxy flavone will be trifluoromethylated in the same fashion. The last
step will involve refluxing the trifluoromethylated flavone using hydrobromic acid to afford the
trihydroxyphenly flavone (Scheme 2.9).

Scheme 2.7: Radical trifluoromethylation by using trifluoroiodomethane gas
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Scheme 2.8: Trifluoromethylation of flavone by using Umemoto′s and Togni′s reagent

Scheme 2.9: Trifluoromethylation of flavone by using Umemoto′s or Togni′s reagent then
demethylation with hydrobromic acid
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CHAPTER 3
BIOLOGICAL EVOLUTION OF THE FLUORINATED FLAVONOIDS
3.1 The DPPH antioxidant assay
1,1-Diphenyl-2-picryl-hydrazyl (DPPH) is a free radical that is stable at room temperature
and is a common reagent in an antioxidant assay based on electron-transfer mechanism. DPPH,
produces a violet solution but when it is reduced in the presence of an antioxidant, DPPH will turn
colorless. [27] The DPPH antioxidant assay is performed by using a 96-well plate and measure the
scavenging activity toward the 2,2-diphenyl-1-picrylhydrazyl free radical. Many studies are
conducted to measure the antioxidant activity of flavonoids using DPPH assay. [7,4]
Mira and co-workers measured the antioxidant activity of various flavonoids against DPPH
radical. The flavones myricetin, quercetin, kaempferol, and luteolin were tested. Flavone and
DPPH were mixed for 30 min then absorbance measured at 517 nm. The results are summarized
in Table 4 and indicated how scavenging activity increases with increasing the number of the free
OH group (Table 3.1). [28]
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Table 3.1: DPPH scavenging activity of hydroxy-flavones

Flavones

Mmol DPPH scavenged per
mmol flavonoid

Structure

Myricetin

5.7 ± 0.3

2.9 ± 0.1
Quercetin

2.7 ± 0.1
Luteolin

2.2 ±0.2
Kaempferol
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3.1.1 Results
The scavenging activity of flavones 5 and 6 and their monofluorinated derivatives 12 and
13 in concentration ranging from (1.5625 – 200 μg/mL) were evaluated against 0.1 mM of DPPH
by the decrease of absorbance at 517 nm. The data indicate that the monofluorinated flavones are
more potent than the un-fluorinated derivatives. For example, the EC50 of 6 dropped from 37.14
μg/mL to 0.2359 μg/mL for the fluorinated 13. Also, the EC50 of the methoxy flavone 5 dropped
from 71.66 to 0.3345 μg/mL when compared with the fluorinated methoxy flavone 12 (Table
4.2) and (Figure 3.1).
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Table 3.2: Flavones used in DPPH assay and their EC50 values.
Compound

EC50 ± SD (μg/mL)

71.66 ± 0.04

37.14 ± 0.02

0.3345 ± 0.017

0.2359 ± 0.035

0.1596 ±0.034
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Figure 3.1: DPPH assay results
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3.2 neuroprotective assay
neuroprotective assay is used to measure the cell viability in response to many substrates
like growth factors, cytokines and cytotoxic reagent. In our case we will be testing the synthesized
flavones and their fluorinated derivatives. This assay is based on the reduction of the 3-(4,5dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium

(MTS)

tetrazolium compound by viable mammalian cells (neurons) to generate a colored formazan dye
that is soluble in cell culture media and can be quantified by measuring the absorbance at 490-500
nm.

Figure 3.2: Structures of MTS
3.2.1 Results
The neuroprotective activity of flavones 5 and 6 and their monofluorinated derivatives 12
and 13 in concentration ranging from (40 – 0.31 μM) were evaluated against glutamate by
measuring the absorbance of the reduced form of TMS at 490 nm. The data indicates that the unfluorinated hydroxy flavones shows more neuroprotective activity than the monofluorinated
hydroxy derivative. While the monofluorinated hydroxy derivative was more active then unfluorinated methoxy flavones (Figure 3.3).
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Figure 3.3: Neuroprotective assay results
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CHAPTER 4
CONCLUSION
The synthesis of the desired flavones and their monofluorinated and trifluoromethylated
derivative was successful. Pyridine was used in the key step to increase the yield 32% to 72% and
reduce the reaction time from one week to 12 hours. The biological evaluation of the flavonoids
was carried out by using two assays, DPPH antioxidant assay and MTS cell proliferation assay.
DPPH antioxidant assay was preformed on the flavones and their monofluorinated flavones. The
results indicate that the monofluorinated flavones are more potent than un-fluorinated flavones.
Fluorinated and un-fluorinated flavones have potential neuroprotective activity. Using 19F NMR
to understand the impact of fluorination on the antioxidant activity of flavones is still in progress.
The preliminary data are not conclusive about the effect of fluorination and therefore more NMR
experiments are required.
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CHAPTER 5
Experimental Details
5.1 Synthesis of Flavonoids

+

2-Acetylphenyl 3,4,5-trimethoxybenzoate 3. A mixture of 1-(2-hydroxyphenyl)ethan-1one 1 (200 mg, 1.47 mmol) and 3,4,5-trimethoxybenzoyl chloride 2 (404 mg, 1.76 mmol) in
pyridine (3 mL) was heated at 70 °C under air. After 12 h, the reaction mixture was cooled to 0
°C, then acidified by adding 1 M of aqueous HCl (3 mL), and the resultant mixture was extracted
with EtOAc (10 mL × 3). The organics were dried over Na2SO4 and concentrated under reduced
pressure. SiO2 flash chromatography (7:3 hexanes/EtOAc) afforded the 2-acetylphenyl 3,4,5trimethoxybenzoate product 3 as a white solid (357 mg) in 73% yield: 1H NMR (400 MHz,
CDCl3) δ 7.66 (dd, J = 7.8, 1.5 Hz, 1H), 7.39 (t, J = 8.5 Hz, 1H), 7.17 (t, J = 7.6 Hz, 1H), 7.06
(s, 2H), 7.03 (d, J = 8.1 Hz, 1H), 3.74 (s, 6H), 3.73 (s, 3H), 2.35 (s, 3H).
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(Z)-3-hydroxy-1-(2-hydroxyphenyl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one 4. A
mixture of 2-acetylphenyl 3,4,5-trimethoxybenzoate 3 (200 mg, 0.60 mmol) and potassium
hydroxide (60 mg, 1.06 mmol) in pyridine (3 mL) was heated at 50 °C under air. After 12 h, the
reaction mixture was cooled to 0 °C, then acidified by adding 1M of aqueous HCl (3 mL), and
the resultant mixture was extracted with EtOAc (10 mL × 3). The organics were dried over
Na2SO4 and concentrated under reduced pressure. SiO2 flash chromatography (7:3
hexanes/EtOAc) afforded the (Z)-3-hydroxy-1-(2-hydroxyphenyl)-3-(3,4,5trimethoxyphenyl)prop-2-en-1-one product 4 as a yellow solid (160 mg) in 81% yield: 1H NMR
(500 MHz, CDCl3) δ 15.72 (s, 1H), 12.02 (s, 1H), 7.74 (d, J = 7.9 Hz, 1H), 7.43 (t, 1H), 7.13 (S,
2H), 6.97 (d, J = 8.3 Hz, 1H), 6.89 (t, J = 7.5 Hz, 1H), 6.71 (s, 2H), 3.93 (s, 6H), 3.91 (s, 3H).

2-(3,4,5-Trimethoxyphenyl)-4H-chromen-4-one 5. A mixture of (Z)-3-hydroxy-1-(2hydroxyphenyl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one 4 (10 mg, 0.03 mmol) and iron(III)
chloride (0.47 mg , 0.0087 mmol) in dichloromethane (1 mL) was stirred at rt under air. After 24
h, the reaction mixture was extracted with dichloromethane (1 mL × 3). The organics were dried
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over Na2SO4 and concentrated under reduced pressure to afford the 2-(3,4,5-trimethoxyphenyl)4H-chromen-4-one 5 (8.3 mg) in 89% yield: 1H NMR (500 MHz, CDCl3) δ 8.24 (d, J = 7.9 Hz,
1H), 7.72 (t, J = 7.7 Hz, 1H), 7.60 (d, J = 8.3 Hz, 1H), 7.44 (t, J = 7.3 Hz, 1H), 7.15 (s, 2H), 6.83
(s, 1H), 3.97 (s, 6H), 3.94 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 178.32, 163.26, 156.24,
153.64, 141.32, 133.77, 127.02, 125.72, 125.31, 123.96, 118.11, 107.40, 103.85, 77.48, 77.16,
76.84, 61.08, 56.42.

2-(3,4,5-Trihydroxyphenyl)-4H-chromen-4-one 6. A mixture of 2-(3,4,5trimethoxyphenyl)-4H-chromen-4-one 5 (10 mg, 0.03 mmol) in hydrobromic acid (1 mL) was
stirred in a sealed tube at 100 °C. After 24 h, the reaction mixture was cooled to rt and
concentrated under reduced pressure to afford the 2-(3,4,5-trihydroxyphenyl)-4H-chromen-4-one
6 (8.1 mg) in quantitative yield: 1H NMR (400 MHz, acetone-d6) δ 8.10 (d, J = 7.5 Hz, 1H), 7.78
(t, J = 8.4 Hz, 1H), 7.67 (d, J = 8.4 Hz, 1H), 7.46 (t, J = 7.4 Hz, 1H), 7.14 (s, 2H), 6.60 (s, 1H),
2.80 (s, 3H); 13C NMR (101 MHz, DMSO) δ 176.93, 163.67, 155.64, 146.51, 137.80, 134.22,
125.43, 124.83, 123.36, 120.79, 118.35, 105.81, 104.86, 40.15, 39.94, 39.73, 39.52, 39.31, 39.10,
38.89.
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5.2 Synthesis of Monofluorinated Flavonoids

(E)-2-fluoro-3-hydroxy-1-(2-hydroxyphenyl)-3-(3,4,5-trimethoxyphenyl)prop-2-en1-one 10. A mixture of (Z)-3-hydroxy-1-(2-hydroxyphenyl)-3-(3,4,5-trimethoxyphenyl)prop-2en-1-one 4 (10 mg, 0.03 mmol), and N-fluorobenzenesulfonimide (11.88 mg, 0.036 mmol) in
pyridine (1 mL) was stirred at rt under air. After 24 h, the reaction mixture was cooled to rt and
water (2 mL) was added. The reaction mixture was cooled to 0 °C, then acidified by adding 2 M
of aqueous HCl (3 mL), and the resultant mixture was extracted with Et2O (2 mL × 5). The
organics were dried over Na2SO4 and concentrated under reduced pressure. SiO2 flash
chromatography (7:3 hexanes/EtOAc) followed by prep. TLC by using (7:3 hexanes/EtOAc) to
afforded the (E)-2-fluoro-3-hydroxy-1-(2-hydroxyphenyl)-3-(3,4,5-trimethoxyphenyl)prop-2-en1-one 10 (5.89 mg) in 49% yield: 1H NMR (500 MHz, CDCl3) δ 15.72 (s, 1H), 12.02 (s, 1H),
7.74 (d, J = 7.9 Hz, 1H), 7.43 (t, 1H), 7.13 (S, 2H), 6.97 (d, J = 8.3 Hz, 1H), 6.89 (t, J = 7.5 Hz,
1H), 6.51 (d, J = 48.8 Hz, 1H), 3.93 (s, 6H), 3.91 (s, 3H);19F NMR (300 MHz, CDCl3) –186.17
(d, J = 48.9 Hz)
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3-Fluoro-2-(3,4,5-trimethoxyphenyl)- 4H-chromen-4-one 12. A mixture of (E)-2fluoro-3-hydroxy-1-(2-hydroxyphenyl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one 10 (10 mg,
0.0287 mmol), and iron(III) chloride (0.47 mg , 0.0087 mmol) in dichloromethane (1 mL) was
stirred at rt under air, after 24 h, the reaction mixture was extracted with dichloromethane (1 mL
× 3). The organics were dried over Na2SO4 and concentrated under reduced pressure to afforded
the 3-fluoro-2-(3,4,5-trimethoxyphenyl)-4H-chromen-4-one 12 (7.9 mg) in 84% yield: 1H NMR
(500 MHz, CDCl3) δ 8.24 (d, J = 7.9 Hz, 1H), 7.72 (t, J = 7.7 Hz, 1H), 7.60 (d, J = 8.3 Hz, 1H),
7.44 (t, J = 7.3 Hz, 1H), 7.15 (s, 2H), 3.97 (s, 6H), 3.94 (s, 3H); 13C NMR (101 MHz,
Chloroform-d) δ 170.86 (d, J = 16.7 Hz), 150.78 (d, J = 23.2 Hz), 146.09 (d, J = 247.8 Hz),
141.14 (d, J = 1.6 Hz), 125.98 (d, J = 3.3 Hz), 124.24 (d, J = 7.1 Hz), 123.86 (d, J = 5.1 Hz),
105.81 (d, J = 8.5 Hz); 19F NMR (300 MHz, CDCl3) –160.36

3-Fluoro-2-(3,4,5-trihydroxyphenyl)-4H-chromen-4-one 13. A mixture of 3-fluoro-2(3,4,5-trimethoxyphenyl)-4H-chromen-4-one 12 (10 mg, 0.03 mmol) in hydrobromic acid (1
mL) was stirred in a sealed tube. After 24 h, the reaction mixture was cooled to rt and
concentrated under reduced pressure to afford the 3-fluoro-2-(3,4,5-trimethoxyphenyl)-4H35

chromen-4-one 13 (8.6 mg) in quantitative yield: 1H NMR (400 MHz, DMSO-d6) δ 8.11 (d, J =
9.0 Hz, 1H), 7.90–7.80 (m, 1H), 7.74 (d, J = 8.1 Hz, 3H), 7.58–7.46 (m, 2H), 7.07 (s, 2H), 3.90
(s, 0H); 13C NMR (101 MHz, DMSO-d6) δ 169.42 (d, J = 16.8 Hz), 151.19 (d, J = 23.3 Hz),
146.36–143.72 (m), 137.48 (d, J = 1.3 Hz), 124.91 (d, J = 3.4 Hz), 123.57 (d, J = 7.1 Hz), 117.85
(d, J = 5.2 Hz), 107.40 (d, J = 8.5 Hz); 19F NMR (400 MHz, DMSO) δ –165.19
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5.3 Synthesis of Trifluoromethylated Flavonoids

3-(Trifluoromethyl)-2-(3,4,5-trihydroxyphenyl)-4H-chromen-4-one 15. A mixture of
2-(3,4,5-trihydroxyphenyl)-4H-chromen-4-one 5 (10 mg, 0.032 mmol), copper(I) iodide (0.6 mg,
0.0032 mmol) and 5-(trifluoromethyl)dibenzothiophenium trifluoromethanesulfonate
(Umemoto's reagent) (10 mg, 0.048 mmol) in DMF (1 mL) was heated at 80 °C under argon.
After 34 h, the resultant mixture was extracted with diethyl ether (2 mL × 5). The organics were
dried over Na2SO4 and concentrated under reduced pressure to afford the 3-(trifluoromethyl)-2(3,4,5-trihydroxyphenyl)-4H-chromen-4-one. 20% estimated 19F NMR yield; 1H NMR (500
MHz, CDCl3) δ 8.24 (d, J = 7.9 Hz, 1H), 7.72 (t, J = 7.7 Hz, 1H), 7.60 (d, J = 8.3 Hz, 1H), 7.44
(t, J = 7.3 Hz, 1H), 7.15 (s, 2H), 3.97 (s, 6H), 3.94 (s, 3H); 19F NMR (300 MHz, CDCl3) –56 (s,
3F).
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5.4 The DPPH antioxidant assay
0.2 M stock solution of DPPH in 1:1 ethanol and acetone solution was prepared, and also,
1 mg/mL stock solution of the flavones in 1:1 ethanol and acetone solution. The positive control
was vitamin C and it was prepared with concertation of 1 mg/mL in 1:1 ethanol and acetone
solution. All the stock solutions were prepared daily and stored in the refrigerator in dark.
5.4.1 Preparation:
Fill all the wells with 100 μL of (1:1) ethanol-acetone solution then add to ( A2 to A7 ) of
the well 100 μL of the stock solution of the test flavones and prepare a serial dilution of (200, 100,
50, 25, 12.5, 6.25 and 3.125 μg/mL) by using the appropriate size of micropipette moving from A
to H as seen in (Table 5.1). Next add 100 μL of DPPH solution to all the wells except the blanks,
the plate must be covered all time to minimize evaporation and kept away from light in room
temperature and left for 20 minutes then measure the absorbance at 517 nm
5.4.2 Calculation
% DPPH scavenging = [1-(Abs Sample with DPPH–Abs Sample Blank)]/[(Abs DPPH) –
(Abs Solvent)] x 100
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Table 5.1: 96-well plate arrangement

1

A

B

C

D

E

F

H

Control
DPPH
0.1
mM
DPPH
0.1
mM
DPPH
0.1
mM
DPPH
0.1
mM
DPPH
0.1
mM
DPPH
0.1
mM
DPPH
0.1
mM

2
Sample 1
(Blank)
Sample 1
200
μg/mL
Sample 1
100
μg/mL
Sample 1
50
μg/mL
Sample 1
25
μg/mL
Sample 1
12.5
μg/mL
Sample 1
6.25
μg/mL
Sample 1
3.125
μg/mL

3
Sample 1
+ DPPH
Sample 1
200
μg/mL
Sample 1
100
μg/mL
Sample 1
50
μg/mL
Sample 1
25
μg/mL
Sample 1
12.5
μg/mL
Sample 1
6.25
μg/mL
Sample 1
3.125
μg/mL

4
Sample 1
(Blank)
Sample 1
200
μg/mL
Sample 1
100
μg/mL
Sample 1
50
μg/mL
Sample 1
25
μg/mL
Sample 1
12.5
μg/mL
Sample 1
6.25
μg/mL
Sample 1
3.125
μg/mL

5
Sample 1
+ DPPH
Sample 1
200
μg/mL
Sample 1
100
μg/mL
Sample 1
50
μg/mL
Sample 1
25
μg/mL
Sample 1
12.5
μg/mL
Sample 1
6.25
μg/mL
Sample 1
3.125
μg/mL

6
Sample 1
(Blank)
Sample 1
200
μg/mL
Sample 1
100
μg/mL
Sample 1
50 μg/mL

7
Sample 1
+ DPPH
Sample 1
200 μg/mL

Sample 1
25 μg/mL

Sample 1
25 μg/mL

Sample 1
12.5
μg/mL
Sample 1
6.25
μg/mL
Sample 1
3.125
μg/mL

Sample 1
12.5 μg/mL

Figure 5.1: Procedure for DPPH assay
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Sample 1
100 μg/mL
Sample 1
50 μg/mL

Sample 1
6.25 μg/mL
Sample 1
3.125
μg/mL

5.5 Neuroprotective assay
Before culturing the neurons, the 96-well plate was coated with 60 μL of 0.01% Poly-LLysine and incubated for 24 hours then washed with distilled water. Next, the neurons were
cultured in a 96-well plate with 100 μL growth media that include neurobasal media, Lglutamine, fetal bovine serum (FBS), and Pen Strep and incubated for 24 hours. The growth
media was replaced by a media that doesn’t contain the fetal bovine serum (FBS), and the plate
was then incubated for one week. Next, it was treated with glutamate and the test compound.
After 24 h the MTS assay was performed by using CellTiter 96 AQueous One Solution
Reagent.

Figure 5.2: Procedure for neuroprotective assay
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